Immunotherapy (IO), in the form of immune checkpoint inhibitors (ICI), is the standard first-line (1L) therapy in patients affected by non-small cell lung cancer (NSCLC) without epidermal-growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.